IP Library Granted Patent US 11,752,097
Granted Patent B2
US 11,752,097 · App. 17/857,587 · Granted Sep 12, 2023

N-acetylcysteine compositions and methods

Inventors: Ronald Domalaon (Raritan, NJ); Jinjiang Li (Monmouth Junction, NJ); Tushar Hingorani (Bridgewater, NJ); Kumaresh Soppimath (Skillman, NJ)
Assignee: ENDO VENTURES LIMITED
A61K9/0019A61K31/19A61K47/02A61K47/26A61J1/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,752,097
App. No.
17/857,587
Granted
Sep 12, 2023
Kind
B2
Abstract

Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.

Claims (15)

1. A sterile and ready-to-administer N-acetylcysteine composition, comprising:

an aqueous solution containing N-acetylcysteine at a concentration suitable for direct administration via intravenous injection to a patient without dilution prior to administration;

wherein the composition has a pH of between 6.0 and 7.5 and comprises a chelating agent at a concentration of between 10 and 60 mcg/mL; and

wherein the ready-to-administer composition contains, after storage over at least three weeks at 80° C., equal or less than 7% total impurities generated from degradation of the N-acetylcysteine.

2. The composition of claim 1 wherein the N-acetylcysteine concentration is 25 mg/mL or 50 mg/mL.

3. The composition of claim 1 wherein the composition has a pH of 7.0±0.2.

4. The composition of claim 1 wherein composition contains, after storage over at least three weeks at 80° C., equal or less than 6% total impurities generated from degradation of the N-acetylcysteine.

5. A kit comprising:

a primary container that contains a sterile and ready-to-administer N-acetylcysteine composition according to claim 1 ;

a secondary container enclosing the primary container, and a non-contact oxygen absorbing agent in a space between the primary and secondary container;

wherein the primary container contains between 100 and 500 mL of the ready-to-administer N-acetylcysteine composition; and

wherein the secondary container is impermeable to light or comprises a metal or metal layer.

6. The kit of claim 5 wherein the primary container contains 200 mL or 250 mL or 300 mL of the ready-to-administer N-acetylcysteine composition.

7. The kit of claim 5 wherein the primary and secondary containers are polymeric bags.

8. The kit of claim 5 wherein the ready-to-administer N-acetylcysteine composition is preservative-free.

Assignments (11)
SHORT FORM INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 6, 2025
From: PH HEALTH LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 073508/0830 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (068031/0059) Recorded Aug 4, 2025
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: ENDO OPERATIONS LIMITED
Reel/Frame 072346/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2025
From: ENDO OPERATIONS LIMITED
To: PH HEALTH LIMITED
Reel/Frame 072131/0540 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 068031/0059 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068031/0202 →
CHANGE OF NAME Recorded Mar 5, 2024
From: OPERAND PHARMACEUTICALS III LIMITED
To: ENDO OPERATIONS LIMITED
Reel/Frame 066732/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: ENDO VENTURES UNLIMITED COMPANY
To: OPERAND PHARMACEUTICALS III LIMITED
Reel/Frame 066732/0137 →
CHANGE OF NAME Recorded Mar 5, 2024
From: ENDO VENTURES LIMITED
To: ENDO VENTURES UNLIMITED COMPANY
Reel/Frame 066732/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2023
From: NEVAKAR INC.
To: NEVAKAR INJECTABLES INC.
Reel/Frame 062711/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2023
From: NEVAKAR INJECTABLES INC.
To: ENDO VENTURES LIMITED
Reel/Frame 062711/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2023
From: DOMALAON, RONALD; LI, JINJIANG; HINGORANI, TUSHAR; SOPPIMATH, KUMARESH
To: NEVAKAR INC.
Reel/Frame 062762/0185 →